Heart failure (HF) is a common, costly and potentially fatal cause of hospitalisation, 1 which has seen a steady and significant increase in recent years. 2 It is a risk factor for the development of pulmonary embolism (PE) in hospitalised patients, as consequence of vascular anomalies, hypercoagulability, an impaired blood flow, 3,4 although large differences exist in the reported frequency of venous thromboembolic events in individuals with HF. 5 On the other hand, this disease seems to be an independent predictor of mortality in patients presenting with acute PE. 6,7 Moreover, PE could be an independent predictor of rehospitalisation or death among patients with HF.